David A. Roth
2021 - Syros Pharmaceuticals
In 2021, David A. Roth earned a total compensation of $1.6M as Chief Medical Officer at Syros Pharmaceuticals, a 35% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $185,158 |
|---|---|
| Option Awards | $944,646 |
| Salary | $482,385 |
| Other | $576 |
| Total | $1,612,765 |
Roth received $944.6K in option awards, accounting for 59% of the total pay in 2021.
Roth also received $185.2K in non-equity incentive plan, $482.4K in salary and $576 in other compensation.
Rankings
In 2021, David A. Roth's compensation ranked 6,940th out of 12,406 executives tracked by ExecPay. In other words, Roth earned more than 44.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,940 out of 12,406 | 44th |
Division Manufacturing | 3,032 out of 5,494 | 45th |
Major group Chemicals And Allied Products | 1,343 out of 2,369 | 43rd |
Industry group Drugs | 1,198 out of 2,090 | 43rd |
Industry Pharmaceutical Preparations | 872 out of 1,537 | 43rd |
Source: SEC filing on April 21, 2022.
Roth's colleagues
We found three more compensation records of executives who worked with David A. Roth at Syros Pharmaceuticals in 2021.
News
Syros Pharmaceuticals CEO Nancy Simonian's 2022 pay rises 12% to $3.5M
April 21, 2023
Syros Pharmaceuticals CEO Nancy Simonian's 2021 pay jumps 23% to $3.1M
April 21, 2022
Syros Pharmaceuticals CEO Nancy Simonian's 2020 pay falls 30% to $2.5M
April 29, 2021
Syros Pharmaceuticals CEO Nancy Simonian's 2019 pay rises 19% to $3.6M
April 28, 2020
Syros Pharmaceuticals CEO Nancy Simonian's 2018 pay jumps 36% to $3M
April 25, 2019